Zydus Lifesciences share price
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,184.40up ₹8.90 (0.76%)BSE ₹1,186.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,175.50.
29 Oct: open ₹1,175.50, high ₹1,187.80, low ₹1,170.50
52-week range of traded prices to 29 Oct 2026
₹835.50Low, 2 Apr 2026₹1,232.10High, 29 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,18,144 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.18
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 23.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.36
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,55,85055.6% delivered
About Zydus Lifesciences
Zydus Lifesciences Limited is an Indian drug maker that researches, makes and sells generic and branded medicines, specialty medicines, biosimilars (close copies of biologic drugs), vaccines and active pharmaceutical ingredients (APIs, the drug substance inside a medicine).1 It also sells consumer wellness products and medical devices, and serves patients in regulated markets (those with strict drug regulators) and emerging markets.21 Its registered and corporate office is in Ahmedabad.3
The business is reported in 3 segments: pharmaceuticals, consumer wellness and medical technology.2 Pharmaceuticals covers formulations (finished medicines) sold in India, North America and international markets, plus APIs and alliances.2 Consumer wellness is run by its subsidiary Zydus Wellness Limited, whose brands include Glucon D, Complan, Sugar Free, Nycil, Everyuth, Nutralite and RiteBite Max Protein.4 Medical technology focuses on orthopaedics, cardiology and nephrology (kidney care).5 In the US, its subsidiary Sentynl Therapeutics sells medicines for ultra-rare diseases.6
The group traces its roots to a company founded in 1952 by Ramanbhai B. Patel; Zydus Lifesciences Limited was incorporated in 1995.78 It entered medical technology by buying Amplitude Surgical, a French orthopaedic company focused on knee and hip implants, taking 85.6% on 29 Jul 2025 and the remaining 14.4% on 24 Oct 2025.95 On 15 Jan 2026 it bought 2 biologics plants in Emeryville and Berkeley, California, from Agenus, entering contract development and manufacturing of biologic drugs for other companies.10
Pankaj R. Patel is non-executive Chairman and his son, Sharvil P. Patel, is Managing Director.11
Zydus Lifesciences key points
Results
- In the quarter to Jun 2026, consolidated revenue rose 22% to ₹80.2 billion; EBITDA (profit before interest, tax, depreciation and amortisation) was ₹19.3 billion, a 24.1% margin, and net profit ₹9.4 billion.12
- In the year to Mar 2026, consolidated revenue rose 17% to ₹271.5 billion and EBITDA rose 20% to ₹84.8 billion, a 31.2% margin; the company says both were its highest ever.131415
- Profit after tax adjusted for one-off items, the company's measure, rose 15% to ₹54.6 billion in the year to Mar 2026, from ₹47.5 billion a year earlier.16
- Net debt (borrowings less cash) was 0.7 times EBITDA at 30 Jun 2026.17
Market position
- Zydus is the 3rd largest US generics company by prescriptions; at Jun 2026 it sold 274 products there, ranking first in about 24% of its product families and in the top 3 in about 60%.18
- In India Zydus ranks first in oncology (cancer medicines), the company says, as of Jun 2026.19
- In India, 5 of its 7 main consumer wellness brands rank first in their categories, by market research and company estimates to Jun 2026.19
Business segments
- Revenue by business (₹ million)202122
Item year to Mar 2026 year to Mar 2025 North America formulations 1,16,820 1,10,500 India formulations 65,740 59,281 Consumer wellness 39,134 26,810 International markets formulations 30,700 21,947 MedTech 7,823 – - India formulations. Chronic and sub-chronic (long-lasting) conditions made up 54.2% of its India portfolio as of Jun 2026, up 360 basis points (hundredths of a percentage point) in 4 years; branded sales grew 20% in the quarter to Jun 2026.2324
- North America formulations. Branded products made up 10% of US revenue in the quarter to Jun 2026. At Mar 2026 it sold 3 US rare-disease medicines: Nulibry, Zokinvy and Zycubo.2526
Plants and capacity
- Zydus has 44 manufacturing facilities, 38 in India and the rest in the US, UK, France, Brazil and Myanmar; 16 have been inspected by the US Food and Drug Administration (USFDA).27
- Zydus's installed capacity at Mar 2026 was 39,018 million pills (tablets and capsules) and 342.9 million injectable units.28
- As of its annual report of 10 Jul 2026, the company was building an automated tablet and capsule plant, Unit III, in Ahmedabad and a dialyser plant for kidney care.29
Research and development
- R&D spending was ₹22,732 million in the year to Mar 2026, 8.4% of revenue and 23% more than the ₹18,555 million of a year earlier; the company has more than 1,500 scientists in 10 R&D centres.3031
- Saroglitazar, its first new chemical entity (a drug it invented), sells in India as Lipaglyn and Bilypsa (₹4.81 billion in market-audit sales, year to Jun 2026); at its call of 11 Aug 2026, its US application had USFDA priority review.323334
- In India Zydus has 16 approved biosimilars, 15 launched, and its biosimilar pipeline has 13 more; it has 16 vaccines with marketing authorisation in India, with 12 in development.3536
What the company expects
- On its earnings call of 11 Aug 2026, the company said it expects double-digit revenue growth and an EBITDA margin of about 24% in the year to Mar 2027.3738
- On its earnings call of 11 Aug 2026, the company said it aims to raise the EBITDA margin to 28% to 30% over about 5 years.39
- On its earnings call of 11 Aug 2026, the company said it expects capital spending of about ₹1,500 crore to ₹1,600 crore in the year to Mar 2027, and branded products to exceed two-thirds of revenue over the medium term.4041
- In its presentation of 23 Aug 2026, the company said it expects USFDA approval of Saroglitazar for primary biliary cholangitis (a long-term liver disease) by the quarter to Mar 2027.42
Recent events
- On 13 Oct 2026, the company and Formycon announced USFDA acceptance for review of FYB206, a proposed biosimilar of the cancer drug Keytruda, which the company licensed for the US and Canada.4344
- On 16 Jun 2026, the company announced it had completed buying US-based Assertio Holdings, agreed in May 2026 for $166 million; Assertio's Rolvedon prevents febrile neutropenia (fever with low white blood cell counts) during chemotherapy.4546
Litigation and regulatory matters
- USFDA inspections ended with 1 observation (an issue noted by inspectors), none on data integrity, at the SEZ II plant on 28 Sep 2026 and 5 at the Moraiya plant on 13 Oct 2026.4748
- At 31 Mar 2026 no plant was under regulatory surveillance or a warning letter (a formal notice of serious violations); the Jarod injectables plant resolved its USFDA warning letter during the year.49
- In the year to Mar 2026 it settled US litigation with the original drug's maker over generic Mirabegron extended-release tablets, paying $120 million plus per-unit royalties until September 2027, and can keep selling it.50
Last updated
All 50 sources, each with its page
- 1. Annual report, 10 Jul 2026, page 8
- 2. Annual report, 10 Jul 2026, page 90
- 3. Annual report, 10 Jul 2026, page 3
- 4. Annual report, 10 Jul 2026, page 94
- 5. Annual report, 10 Jul 2026, page 95
- 6. Annual report, 10 Jul 2026, page 29
- 7. Annual report, 10 Jul 2026, page 6
- 8. Annual report, 10 Jul 2026, page 158
- 9. Annual report, 10 Jul 2026, page 99
- 10. Annual report, 10 Jul 2026, page 99
- 11. Annual report, 10 Jul 2026, page 135
- 12. Earnings call, 11 Aug 2026, page 3
- 13. Annual report, 10 Jul 2026, page 10
- 14. Annual report, 10 Jul 2026, page 96
- 15. Annual report, 10 Jul 2026, page 33
- 16. Annual report, 10 Jul 2026, page 96
- 17. Earnings call, 11 Aug 2026, page 3
- 18. Investor presentation, 23 Aug 2026, page 17
- 19. Investor presentation, 23 Aug 2026, page 5
- 20. Annual report, 10 Jul 2026, page 93
- 21. Annual report, 10 Jul 2026, page 92
- 22. Annual report, 10 Jul 2026, page 95
- 23. Earnings call, 11 Aug 2026, page 4
- 24. Earnings call, 11 Aug 2026, page 3
- 25. Earnings call, 11 Aug 2026, page 6
- 26. Annual report, 10 Jul 2026, page 92
- 27. Annual report, 10 Jul 2026, page 35
- 28. Annual report, 10 Jul 2026, page 36
- 29. Annual report, 10 Jul 2026, page 36
- 30. Annual report, 10 Jul 2026, page 33
- 31. Annual report, 10 Jul 2026, page 13
- 32. Annual report, 10 Jul 2026, page 91
- 33. Investor presentation, 23 Aug 2026, page 14
- 34. Earnings call, 11 Aug 2026, page 6
- 35. Investor presentation, 23 Aug 2026, page 26
- 36. Investor presentation, 23 Aug 2026, page 27
- 37. Earnings call, 11 Aug 2026, page 7
- 38. Earnings call, 11 Aug 2026, page 8
- 39. Earnings call, 11 Aug 2026, page 17
- 40. Earnings call, 11 Aug 2026, page 9
- 41. Earnings call, 11 Aug 2026, page 5
- 42. Investor presentation, 23 Aug 2026, page 24
- 43. Exchange filing, 13 Oct 2026, page 2
- 44. Exchange filing, 13 Oct 2026, page 3
- 45. Exchange filing, 16 Jun 2026, page 2
- 46. Annual report, 10 Jul 2026, page 29
- 47. Exchange filing, 28 Sep 2026, page 2
- 48. Exchange filing, 13 Oct 2026, page 2
- 49. Annual report, 10 Jul 2026, page 39
- 50. Annual report, 10 Jul 2026, page 92
Results
Consolidated; ₹ crore.Zydus Lifesciences quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +21.1%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −1.3%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹8,017 Crup 5.67%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹990 Crdown 26.16%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 12.4%
Revenue by quarter
Peak revenue ₹8,017 Cr, quarter to Jun 2026; lowest ₹5,237 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,865 | 7,587 | 8,017 |
| Net profit | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 990 |
| Net margin | 17.6% | 19.5% | 19.1% | 23.1% | 20.2% | 14.9% | 17.7% | 12.4% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹27,148 Crup 16.81%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹5,124 Crup 9.65%
- Net margin
- 18.9%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty. From the year to Mar 2022, the company reports a discontinued business. From the year to Mar 2023, the company's revenue for that year, ₹17,237 Cr, differs from its quarters added, ₹17,580 Cr.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9,625what Revenue, Mar 2017, includes. This period's revenue includes excise duty of ₹196 crore, a tax on the goods the company makes that it collects and pays to the government. | 11,936 | 13,166 | 14,253 | 15,102 | 15,265 | 17,237 | 19,547 | 23,242 | 27,148 |
| Net profit | 1,488 | 1,776 | 1,899 | 1,204 | 2,185 | 4,618 | 2,092 | 3,973 | 4,673 | 5,124 |
| Net margin | 15.5% | 14.9% | 14.4% | 8.5% | 14.5% | – | 12.1% | 20.3% | 20.1% | 18.9% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. Net margin is left blank for Mar 2022: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- PharmaceuticalsPharmaceuticals, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹22,412 Crup 9.09%82.6%
- Consumer productsConsumer products, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹3,954 Crup 46.57%14.6%
- Medical technologiesMedical technologies, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹782 Cr2.9%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the years to Mar 2018, Mar 2022 and Mar 2023: days before it are of the company before the change.Zydus Lifesciences PE ratio and valuation
Price to earnings
At or below today's level on 60% of 2,479 trading days over the last 10 years.
LowestHighest
Its median22.10Industry median28.38
Price to book
At or below today's level on 82% of 1,979 trading days since Nov 2018.
LowestHighest
Its median3.73Industry median2.97
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 8% of 2,479 trading days over the last 10 years.
LowestHighest
Its median0.76%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −1.6% | +11.4% | −11.8% | 0.1% |
| 3 years | +21.6% | +37.4% | −11.9% | 0.6% |
| 5 years | +15.3% | +19.2% | −3.8% | 0.7% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2023 and Mar 2026.
Mutual fund holdings
207 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 120 of the 145 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.All 207 funds holding Zydus Lifesciences
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 7
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 6
- AddedAdded. Funds that held more shares than at the end of the month before.
- 76
- CutCut. Funds that held fewer shares than at the end of the month before.
- 69
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 47
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 7
| Fund | |||
|---|---|---|---|
 Parag Parikh Flexi Cap FundPPFAS Mutual Fund | 1,92,62,784 | 1.54% | ₹2,238.3 Cr |
 Kotak Flexi Cap FundKotak Mahindra Mutual Fund | 1,04,11,615 | 2.28% | ₹1,209.8 Cr |
 HSBC Midcap FundHSBC Mutual Fund | 40,78,983 | 2.82% | ₹474.0 Cr |
 Bandhan Large & Mid Cap FundBandhan Mutual Fund | 29,57,548 | 1.66% | ₹343.7 Cr |
 ICICI Prudential Large Cap FundICICI Prudential Mutual Fund | 24,81,016 | 0.38% | ₹288.3 Cr |
 quant Multi Cap Fundquant Mutual Fund | 23,63,448 | 3.66% | ₹274.6 Cr |
| quant Mid Cap Fundquant Mutual Fund | 20,62,800 | 3.13% | ₹239.7 Cr |
| quant ELSS Tax Saver Fundquant Mutual Fund | 18,08,829 | 1.60% | ₹210.2 Cr |
| quant Aggressive Hybrid Fundquant Mutual Fund | 17,44,785 | 9.62% | ₹202.7 Cr |
| quant Flexi Cap Fundquant Mutual Fund | 17,31,923 | 2.75% | ₹201.2 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Zydus Lifesciences insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group1 purchase, 0 sales₹0.10 CrNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹0.10 Cr1 pledge filing of unclear kind · 14 off-market moves
- Directors and key managers: no market trade · 1 off-market move
- Others: no market trade · 2 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Zydus Lifesciences competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Zydus Lifesciences in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical IndustriesSUNPHARMA | 4,22,523 | 34.93 | 5.06 | +11.4% | +16.6% | 15.5% | 16.9% | 0.91% |
 Divi's LaboratoriesDIVISLAB | 2,56,549 | 87.71 | 15.31 | +16.3% | +26.8% | 18.4% | 20.8% | 0.31% |
 Torrent PharmaceuticalsTORNTPHARM | 1,74,208 | 82.02 | 9.48 | +42.1% | −0.7% | 15.8% | 12.0% | 0.83% |
 Laurus LabsLAURUSLABS | 1,21,246 | 110.89 | 22.88 | +22.6% | +114.9% | 22.4% | 19.8% | 0.09% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,12,264 | 40.10 | 2.89 | −3.5% | −51.5% | 7.5% | 6.0% | 0.59% |
 CiplaCIPLA | 1,09,709 | 37.87 | 3.10 | −0.7% | −46.8% | 8.5% | 9.7% | 0.96% |
 Mankind PharmaMANKIND | 1,01,993 | 45.36 | 5.80 | +13.3% | +28.4% | 13.7% | 13.6% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 95,507 | 25.73 | 2.52 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Zydus Lifesciences dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹11.00 a share, year to Mar 2025.
| Ex-date | Type | Per share |
|---|---|---|
| 24 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹1.00 |
| 25 Jul 2025 | Final | ₹11.00 |
| 26 Jul 2024 | Final | ₹3.00 |
| 28 Jul 2023 | Final | ₹6.00 |
| 28 Jul 2022 | Final | ₹2.50 |
| 28 Jul 2021 | Final | ₹3.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Zydus Lifesciences announcements
Oct 2026
24 Oct · Analysts
19 Oct · Board meeting
16 Oct · General Updates
Zydus Lifesciences share price by year
Each calendar year to 2025.Zydus Lifesciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 914.35 | −5.9% | 1,047.85 | 822.10 |
| 2024 | 971.70 | +41.0% | 1,300.90 | 699.15 |
| 2023 | 689.20 | +64.1% | 689.20 | 420.10 |
| 2022 | 419.95 | −13.1% | 477.25 | 330.10 |
| 2021 | 483.15 | +1.3% | 664.95 | 419.75 |
| 2020 | 476.75 | +87.5% | 489.50 | 236.90 |
| 2019 | 254.30 | −27.0% | 355.90 | 213.85 |
| 2018 | 348.45 | −19.6% | 452.00 | 337.40 |
| 2017 | 433.50 | +21.5% | 549.15 | 349.60 |
| 2016 | 356.65 | +8.9% | 424.50 | 296.55 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 1,167.00 | 1,184.30 | 1,155.90 | 1,175.50 | 1,176.88 | 5,66,900 | 52.1% |
| 27 Oct 2026 | 1,155.00 | 1,181.00 | 1,150.60 | 1,172.90 | 1,171.99 | 12,72,268 | 51.4% |
| 26 Oct 2026 | 1,129.40 | 1,160.40 | 1,093.50 | 1,160.40 | 1,139.78 | 24,28,387 | 29.7% |
| 23 Oct 2026 | 1,138.00 | 1,143.50 | 1,118.90 | 1,129.40 | 1,126.34 | 15,03,628 | 52.1% |
| 22 Oct 2026 | 1,116.00 | 1,138.50 | 1,100.30 | 1,135.00 | 1,127.20 | 13,58,088 | 51.1% |
| 21 Oct 2026 | 1,113.70 | 1,126.90 | 1,106.00 | 1,117.30 | 1,112.91 | 7,46,594 | 50.9% |
| 19 Oct 2026 | 1,116.40 | 1,134.20 | 1,110.30 | 1,113.90 | 1,121.07 | 2,53,448 | 44.0% |
| 16 Oct 2026 | 1,140.10 | 1,146.50 | 1,123.00 | 1,123.00 | 1,130.60 | 15,98,906 | 65.1% |
| 15 Oct 2026 | 1,121.00 | 1,150.80 | 1,114.70 | 1,140.20 | 1,135.47 | 11,27,613 | 50.2% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 6 Oct 2015 | Split | 0.2000 | Each share became 5. |
| 5 Apr 2010 | Bonus | 0.6667 | Holders received 1 bonus share for every 2 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- ZYDUSLIFE
- BSE code
- 532321
- ISIN
- INE010B01027
- Industry
- Pharmaceuticals & Biotechnology
- Former symbols
- CADILAHC
- Website
- www.zyduslife.com
- CIN
- L24230GJ1995PLC025878
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1995
- Registered office
- Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Sarkhej - Gandhinagar Highway, Nr. Vaishnodevi Circle, Ahmedabad 382481, Gujarat
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty Next 50, Nifty 100, Nifty 200, BSE 200, Nifty 500, BSE 500